PMN Stock Analysis: Buy, Sell, or Hold?
PMN - ProMIS Neurosciences Inc. Common Shares (ON)
$14.51
-0.40 (-2.68%)
âŧ
5d:
-2.36%
30d:
+15.07%
90d:
+33.73%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When PMN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PMN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PMN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PMN is currently trading at $14.51, which is considered fair relative to its 30-day fair value range of $13.28 to $15.06.
Technical Outlook: Technically, PMN is in a strong uptrend. Immediate support is located at $13.96, while resistance sits at $16.01.
Market Sentiment: PMN scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $44.15 (+196.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PMN is in a strong uptrend. Immediate support is located at $13.96, while resistance sits at $16.01.
Market Sentiment: PMN scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $44.15 (+196.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$13.28 -
$15.06
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 196.1% below Wall St target ($44.15)
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.28 -
$15.06
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$13.96
Resistance Level
$16.01
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.54
Wall Street Target
$44.15
(+196.1%)
Share & Embed Analysis
Last updated: August 24, 2026 8:14 AM ET
Data refreshes hourly during market hours. Next update: 9:14 AM
Data refreshes hourly during market hours. Next update: 9:14 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PMN showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Patrick D Kirwin
BUY
4000 shares
2026-04-22
Eugene Williams
BUY
2000 shares
2026-03-04
Eugene Williams
BUY
1000 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 51 HOLD |
